N-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]acetamide | 1453198-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]acetamide
• CAS: 1453198-88-3
• 化学式: C₁₅H₂₁N₃O₃
• 分子量: 291.35
• InChiKey: VINHWUSUYGUONA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2,5-二氯嘧啶-4-基)-1H-吲哚 、 N-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]acetamide 在 对甲苯磺酸 作用下， 以 N-甲基吡咯烷酮 、 戊醇 为溶剂， 反应 1.0h， 以31%的产率得到1-[4-[4-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone
  参考文献：
  名称：

  Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

  摘要：

  A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design.

  DOI：

  10.1021/jm400822z
• 作为产物：
  描述：

  1-乙酰基-4-[3-(甲基氧基)-4-硝基苯基]哌嗪 在 platinum(IV) oxide 、 氢气 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 25.0 ℃ 、130.0 kPa 条件下， 反应 4.0h， 生成 N-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]acetamide
  参考文献：
  名称：

  Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

  摘要：

  A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design.

  DOI：

  10.1021/jm400822z

文献信息

• Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)
  作者：Richard A. Ward、Mark J. Anderton、Susan Ashton、Paul A. Bethel、Matthew Box、Sam Butterworth、Nicola Colclough、Christopher G. Chorley、Claudio Chuaqui、Darren A. E. Cross、Les A. Dakin、Judit É. Debreczeni、Cath Eberlein、M. Raymond V. Finlay、George B. Hill、Matthew Grist、Teresa C. M. Klinowska、Clare Lane、Scott Martin、Jonathon P. Orme、Peter Smith、Fengjiang Wang、Michael J. Waring

  DOI：10.1021/jm400822z

  日期：2013.9.12

  A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design.